• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ichor touts use of electroporation drug-delivery system in cervical cancer trial

August 21, 2018 By Sarah Faulkner

Ichor Medical Systems

Ichor Medical Systems said today that its TriGrid electroporation drug-delivery system was tapped for a Phase Ib/II clinical trial to administer an investigational therapeutic HPV DNA vaccine, GX-188E, developed by Genexine Inc.

The trial is designed to test the efficacy of a DNA vaccine combined with an anti-PD-1 therapy in patients with HPV-induced advanced non-resectable cervical cancer.

Ichor’s TriGrid device uses electroporation to boost a cell’s permeability and enable entry of a DNA vaccine. The company said its device has been used in more than 25 clinical studies.

A Phase I trial using the TriGrid system to deliver GX-188E in patients with a precancerous stage of cervical cancer showed promise, according to Ichor – the drug triggered a tumor-specific immune response with “evidence of lesion clearance.”

The Phase Ib/II study, which launched in Korea, is slated to enroll up to 46 patients.

“Ichor’s TriGrid Delivery System is a platform technology used by an increasing number of Ichor partners for clinical delivery of their DNA vaccines where T-cell generation is a critical aspect of the prescribed immunotherapy. We are pleased through our Genexine partnership to expand TriGrid’s use into additional areas of immuno-oncology around the world,” Ichor founder & CEO Robert Bernard said in prepared remarks.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Oncology, Pharmaceuticals Tagged With: Ichor Medical Systems

IN CASE YOU MISSED IT

  • Rapid Dose closes first tranche of $5M financing
  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS